Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Trading activity: 177,913 shares traded on Friday (down 12% from 201,325 the prior session); last trade $27.37 vs prior close $27.80, with the 50-day moving average at $29.27 and the 200-day at $26.68.
• Analyst sentiment: UBS and SMBC Nikko upgraded Chugai to "Strong Buy," and MarketBeat shows an average rating of Strong Buy.
• Fundamentals: Market cap $90.08 billion and P/E 31.46; latest quarter EPS $0.25, revenue $2.25 billion, net margin 34.47% and ROE 22%, with analysts forecasting ~0.74 EPS for the year.

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) saw strong trading volume on Friday . 177,913 shares changed hands during mid-day trading, a decline of 12% from the previous session's volume of 201,325 shares.The stock last traded at $27.3650 and had previously closed at $27.80.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. UBS Group upgraded Chugai Pharmaceutical to a "strong-buy" rating in a research report on Tuesday, January 27th. Smbc Nikko Sec. raised Chugai Pharmaceutical to a "strong-buy" rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock has an average rating of "Strong Buy".

Chugai Pharmaceutical Price Performance

The business's 50-day moving average price is $29.27 and its two-hundred day moving average price is $26.68. The company has a market capitalization of $90.08 billion, a price-to-earnings ratio of 31.46 and a beta of 0.69.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The company had revenue of $2.25 billion during the quarter. As a group, research analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai's activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.